Announced
Synopsis
ANP Technologies, an emerging nanobiotechnology company, terminated the merger with Sorrento Therapeutics, an antibody-centric, clinical stage biopharmaceutical company. The effect of this termination now allows ANP to freely explore other business opportunities with parties interested in ANP’s diagnostic and platform drug delivery technologies.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.